April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Long-term results of dexamethasone intravitreal implant for noninfectious uveitic macular edema
Author Affiliations & Notes
  • Zohar Habot-Wilner
    Ophthalmology, Tel-Aviv Medical Center, Tel Aviv, Israel
    Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Nir Sorkin
    Ophthalmology, Tel-Aviv Medical Center, Tel Aviv, Israel
    Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Dafna Goldenberg
    Ophthalmology, Tel-Aviv Medical Center, Tel Aviv, Israel
    Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Michaella Goldstein
    Ophthalmology, Tel-Aviv Medical Center, Tel Aviv, Israel
    Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Footnotes
    Commercial Relationships Zohar Habot-Wilner, None; Nir Sorkin, None; Dafna Goldenberg, None; Michaella Goldstein, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5295. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zohar Habot-Wilner, Nir Sorkin, Dafna Goldenberg, Michaella Goldstein; Long-term results of dexamethasone intravitreal implant for noninfectious uveitic macular edema. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5295. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To report the long-term outcome of the 0.7-mg dexamethasone drug delivery system (DEX-DDS) intravitreal injection for noninfectious uveitic macular edema.

Methods: Retrospective study of eyes with noninfectious uveitic macular edema treated with DEX-DDS injection with at least 6 months follow-up time. Macular edema was diagnosed by clinical examination, fluorescein angiography and Heidelberg Spectralis spectral domain optical coherence tomography (SD-OCT). Patients’ data were collected and included details of uveitis, ocular inflammation, best corrected visual acuity (BCVA) and SD-OCT at baseline and each visit during follow-up. Number of injections and potential complications were recorded.

Results: 8 eyes (7 patients) were included. One eye with anterior uveitis, six eyes with intermediate uveitis and one eye with panuveitis. Mean follow-up time was 17 months. In 1 eye the injection was given as adjunctive treatment. Macular edema resolved in all eyes, 3.9 weeks (range, 1-6.9) post injection. The mean BCVA improvement was 0.25 logMAR (p < 0.05), 3.9 weeks (range, 1-6.9) post injection. Central point thickness improved from 612 ±143 µ to 250 ±55 µ (p < 0.05). Macular edema did not recur in 5 eyes after a mean follow-up of 14.5 months. Macular edema relapsed in 3 eyes (2 patients) after a mean time of 4.7 months (range, 3.6-6.3). These patients had repeated injections; 1 patient had 2 injections and 1 patient had 4 injections with macular edema resolution. Two eyes had intraocular pressure elevation which was well controlled under topical treatment.

Conclusions: Intravitreal DEX-DDS injections resulted in macular edema resolution and visual acuity improvement. Some eyes needed repeated injections, but most eyes achieved long-term resolution. No significant complications were noticed.

Keywords: 746 uveitis-clinical/animal model • 487 corticosteroids • 505 edema  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×